Synthesis and biological evaluation of novel 5,8-disubstituted-2-methyl-2, 3,4,5-tetrahydro-1H-pyrido[4,3-b] indoles as 5-HT6 and H1 receptors antagonists

Archiv der Pharmazie

Volumn 342, Issue 12, 2009, Pages 740-747

  Ivachtchenko, Alexandre V ^a,b   Frolov, Eugene B ^b   Mitkin, Oleg D ^b   Kysil, Volodymyr M ^b   Khvat, Alexander V ^b   Tkachenko, Sergey E ^a,b  

^a Chemical Diversity Research Institute   (Russian Federation)

^b CHEMDIV INC   (United States)

Author keywords

Antagonists; Dimebon; Histamine receptors; Serotonin receptors; Tetrahydro carbolines

Indexed keywords

2 METHYL 5 (PYRIDIN 2 YL) 2,3,4,5 TETRAHYDRO 1H PYRIDO[4,3 B]INDOLE; 2 METHYL 5 (PYRIDIN 3 YL) 2,3,4,5 TETRAHYDRO 1H PYRIDO[4,3 B]INDOLE; 2 METHYL 5 (PYRIMIDINYL 5 YL) 2,3,4,5 TETRAHYDRO 1H PYRIDO[4,3 B]INDOLE; 2 METHYL 5 [2 (PYRIDIN 2 YL)VINYL] 2,3,4,5 TETRAHYDRO 1H PYRIDO[4,3 B]INDOLE; 2 METHYL 5 [2 (PYRIDIN 3 YL)VINYL] 2,3,4,5 TETRAHYDRO1H PYRIDO[4,3 B]INDOLE; 2 METHYL 5 [2 (PYRIDIN 4 YL)VINYL] 2,3,4,5 TETRAHYDRO1H PYRIDO[4,3 B]INDOLE; 2 METHYL 8 FLUORO 5 (PYRIDIN 2 YL) 2,3,4,5 TETRAHYDRO 1H PYRIDO[4,3 B]INDOLE; 2 METHYL 8 FLUORO 5 (PYRIDIN 4 YL) 2,3,4,5 TETRAHYDRO 1H PYRIDO[4,3 B]INDOLE; 2 METHYL 8 FLUORO 5 (PYRIMIDINYL 5 YL) 2,3,4,5 TETRAHYDRO 1H PYRIDO[4,3 B]INDOLE; 2 METHYL 8 FLUORO 5 [2 (PYRIDIN 2 YL)VINYL] 2,3,4,5 TETRAHYDRO 1H PYRIDO[4,3 B]INDOLE; 2 METHYL 8 FLUORO 5 [2 (PYRIDIN 3 YL)VINYL] 2,3,4,5 TETRAHYDRO 1H PYRIDO[4,3 B]INDOLE; 2 METHYL 8 FLUORO 5 [2 (PYRIDIN 4 YL)VINYL] 2,3,4,5 TETRAHYDRO 1H PYRIDO[4,3 B]INDOLE; 2,8 DIMETHYL 5 [2 (PYRIDIN 3YL)VINYL] 2,3,4,5 TETRAHYDRO 1H PYRIDO[4,3-B]INDOLE; 8 FLUORO 2 METHYL 5 (PYRIDIN 3 YLETHYNYL) 2,3,4,5 TETRAHYDRO 1H PYRIDO[4,3 B]INDOLE; DIMEBON; HISTAMINE H1 RECEPTOR ANTAGONIST; INDOLE DERIVATIVE; SEROTONIN 6 ANTAGONIST; TETRAHYDRO GAMMA CARBOLINE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

CARBOLINES; CELL LINE; DRUG EVALUATION, PRECLINICAL; HISTAMINE H1 ANTAGONISTS; HUMANS; INDOLES; RADIOLIGAND ASSAY; RECEPTORS, SEROTONIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 73449090803     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200900056     Document Type: Article

References (52)

1. U. Hörlein, DE Patent No. 930444, 1955.
2. U. Hörlein, Chem. Ber. 1954, 87, 463-472.
3. A. N. Kost, M. A. Yurovskaya, F. A. Trofimov, Khim. Geterotsikl. Soedin. 1973, 3, 291-305.
4. L. Berger, A. J. Corraz, US Patent No. 3522262, 1970 [Chem. Abstr. 1971, 073, 120600z].
5. D. A. Kharkevich, Farmakol. Toksikol. 1967, 20, 6.
6. Y. G. Verhovskiy, L. P. Kokina, Farmakol. Toksikol. 1968, 3, 209.
7. J. R. Phillip, O. J. Paul, US Patent No. 3419568, 1968 [Chem. Abstr. 1969, 070, 068175m].
8. H. Yamamoto, Y. Narfvura, M. Nakao, T. Atsumi, T. Kobayashi, US Patent No. 3535326, 1967 [Chem. Abstr. 1968, 074, 125428e].
9. B. K. Koe, A. Weissman, J. J. Plattner, C. A. Harbert, W. I. M. Welch, Pharmacologist 1979, 21, 180.
10. C. A. Harbert, J. J. Plattner, W. M. Welch, A. Weissman, B. K. Koe, Mol. Pharmacol. 1980, 17, 38-42.
11. C. A. Harbert, J. J. Plattner, W. M. Welch, A. Weissman, B. K. Koe, J. Med. Chem. 1980, 23, 635-643.
12. A. N. Kost, E. V. Vinogradova, K. Daut, A. P. Terent9ev, Zh. Obshch. Khim. 1962, 32, 2050.
13. K. S. Shadurski, I. K. Danusevich, A. N. Kost, E. V. Vinogradova, SU Patent No. 1138164, 1985 [Chem. Abstr. 1985, 102, 198010].
14. N. S. Zefirov, A. Z. Afanas'ev, C. V. Afanas'eva, S. O. Bachurin, et al., RU Patent No. 2140417, 1999.
15. N. S. Zefirov, A. Z. Afanas'ev, S. V. Afanas'eva, S. O. Bachurin, et al., US Patent No. 6187785, 2001 [Der. Abstr. 2001, C1997-258697].
16. N. S. Zefirov, A. Z. Afanas'ev, S. V. Afanas'eva, S. O. Bachurin, et al., US Patent No. 7071206, 2006; M. Abou-Gharbia, U. R. Patel, M. B. Webb, J. A. Moyer, et al., J. Med. Chem. 1987, 30, 1818-1823.
17. J. T. O'Brien, Lancet Neurol. 2008, 7, 768-769; D. T. Hung, A. A. Protter, WO Patent No. 051599, 2008 [Chem. Abstr. 2008, 148, 509951].
18. R. S. Doody, S. I. Gavrilova, M. Sano, R. G. Thomas, et al., Lancet 2008, 372, 207-215.
19. S. Bachurin, T. Bukatina, N. Lermontova, S. Tkachenko, et al., Ann. N. Y. Acad. Sci. 2001, 939, 425.
20. A. Burns, R. Jacoby, Lancet 2008, 372, 207.
21. S. Gauthier, Evid. Based Ment. Health 2009, 12, 21-22; A. Burns, Lancet Neurol. 2009, 8, 4-6.
22. D. Hung, WO Patent No. 041697, 2007 [Chem. Abstr. 2007, 146, 395317].
23. J. Wu, Q. Li, I. Bezprozvanny, Mol. Neurodegener. 2008, 3, 15-26.
24. S. O. Bachurin, V. V. Grigoriev, M. A. Morozova, A. G. Beniashvili, WO Patent No. 087425, 2007 [Chem. Abstr. 2007, 147, 203976].
25. P. A. Galenko-Yaroshevskii, I. L. Cherednik, V. V. Bartashevich, Yu. R. Sheikh-Zade, A. I. Khankoeva, Bull. Exp. Biol. Med. 1997, 124, 691-695.
26. D. Hung, WO Patent No. 036410, 2008 [Chem. Abstr. 2008, 148, 394417].
27. D. Hung, WO Patent No. 036400, 2008 [Chem. Abstr. 2008, 148, 369989].
28. I. A. Matveeva, Farmakol. Toksikol. 1983, 46, 27.
29. E. V. Vinogradova, A. M. Grinev, I. K. Danusevich, M. F. Dzik, et al., Vestn. Akad. Med. Nauk SSSR 1963, 18, 69.
30. N. N. Lermontova, A. E. Redkozubov, E. F. Shevtsova, T. P. Serkova, et al., Bull. Exp. Biol. Med. 2001, 132, 1079-1083.
31. V. V. Grigorev, O. A. Dranyi, S. O. Bachurin, Bull. Exp. Biol. Med. 2003, 136, 474-477.
32. N. N. Lermontova, N. V. Lukoyanov, T. P. Serkova, E. A. Lukoyanova, S. O. Bachurin, Bull. Exp. Biol. Med. 2000, 129, 544-546.
33. S. O. Bachurin, E. P. Shevtsova, E. G. Kireeva, G. F. Oxenkrug, S. O. Sablin, Ann. N. Y. Acad. Sci. 2003, 993, 334.
34. th Int. Conf. Alzheimer's Dis. Relat. Disord. (ICAD), July 26-31, Chicago, 2008, Abst. S4-04-05.
35. S. E. Tkachenko, A. V. Ivachtchenko, A. Khvat, Y. Lavrovsky, I. Okun, 1st International Conference on Drug Design and Discovery, February 2-6, Dubai, 2008, Abst. IL 187.
36. th Int. Conf. Alzheimer's Dis. Relat. Disord. (ICAD), July 26-31, Chicago, 2008, Abst. P2-478.
37. th International Symposium on Medicinal Chemistry, August 31-September 4, Vienna, Austria, 2008, Suppl. P021.
38. B. L. Roth, D. J. Sheffler, W. K. Kroeze, Nat. Rev. Drug Discovery 2004, 3, 353-359.
39. C. Ge9rard, M.-P. Martres, K. Lefèvre, M.-C. Miquel, et al., Brain Res. 1997, 746, 207-219.
40. J. Holenz, P. J. Pauwels, J. L. Diaz, R. Merce, et al., Drug Discovery Today 2006, 11, 283-299.
41. L. A. Dawson, H. Q. Nguyen, P. Li, Neuropsychopharmacology 2001, 25, 662-668.
42. N. Upton, T. T. Chuang, A. J. Hunter, D. J. Virley, Neurotherapeutics 2008, 5, 458-469.
43. W. J. Geldenhuys, C. J. van der Schyf, Curr. Top Med. Chem. 2008, 8, 1035-1048.
44. K. Hirano, T. M. Piers, K. L. Searle, N. D. Miller, et al., Life Sci. 2009, 84, 558-562.
45. A. V. Ivachtchenko, E. B. Frolov, O. D. Mitkin, V. M. Kysil, et al., Bioorg. Med. Chem. Lett. 2009, 19, 3183-3187.
46. J. C. Antilla, A. Klapars, S. L. Buchwald, J. Am. Chem. Soc. 2002, 124, 11684-11688.
47. Y. Zang, R. P. Hsung, M. R. Trscey, K. C. M. Kurtz, E. L. Vera, Org. Lett. 2004, 6, 1151-1154.
48. th Annual Conference & Exhibition. Drug Discovery: From Targets to Candidates, September 11-15, Geneva, Switzerland, 2005, P03021.
49. E. Neher, Neuropharmacology 1995, 34, 1423-1442.
50. G. M. Burgess, P. P. Godfrey, J. S. McKinney, M. J. Berridge, et al., Nature 1984, 309, 63-65.
51. N. Kato, T. Tanaka, K. Yamamoto, Y. Isomura, J. Physiol. 1999, 519, 467-479.
52. G. Grynkiewicz, M. Poenie, R. Y. Tsien, J. Biol. Chem. 1985, 260, 3440-3450.